UK Community Advisory Board (UK-CAB)
Email | |
  • JOIN THE NETWORK

    • UK-CAB 33 – African treatment issues and late diagnosis

    19/03/2010 Alison Neathey
    Off
    Meetings

    Friday 19 March 2010

    At the MRC Clinical Trials Unit, 222 Euston Road, London, NW1

    09:30 – 10:00 Registration, refreshments and expenses
    10:00 – 10:05 Welcome and UKCAB updates
    10:05 – 11:00 African Treatment Issues and Late Diagnosis –Dr Ade Fakoya, HIV Consultant

    • Clinical Issues
    • HPA Late Diagnosis data
    11:00 – 11:15 Break
    11:15 – 12:15 Issues for African sub-groups:

    • Men – Jabulani Chwaula, AHPN, NAHIP
    • MSM – Bisi Alimi, NAZ project
    • Women – Beatrice Osoro, Positively Women
    • Young People
    12:15 – 12:30 Pre-Meeting for Gilead – Brian West
    12:30 – 14:00 Lunch
    14:00 – 15:00 Company meeting: Gilead
    15.00 – 15.15 Break
    15:15 – 15:45 CROI Feedback
    15:45 – 16:00 UKCAB AOB
    16.00 Close

    Background Reading

    This year BHIVA videoed the London feedback meeting and webcasts are now online with slides. This is an alternative way to prepare for Fridays CAB meeting.

    From BHIVA:
    Please go to the BHIVA website for the following downloads:

    Videos of the speakers presentations from the London meeting held on Monday 1 March 2010 were recorded and can be viewed at:
    http://www.bhiva.org/CROI2010London.aspx

    Please use the link below to download the slides
    (For BHIVA members only – login required)
    http://www.bhiva.org/CROI2010Slides.aspx.

    Race Troubles: Why Do African-Americans With HIV Fare Worse?
    http://www.thebody.com/content/art54912.html?ts=pf

    Efavirenz-related studies: genetics, smoking and TDM
    http://i-base.info/htb-south/337HPA 2009

    HIV report in the UK:
    http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1259151891866?p=1249920575999

    Gilead’s HIV Pill Works in Mid-Stage Study
    http://www.thestreet.com/story/10656647/gileads-hiv-pill-works-in-mid-stage-study.html

    42% of Africans with HIV in UK are diagnosed late
    http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1225789252997?p=1204186170287

    HIV prevention for UK Africans should prioritise work with men
    http://www.aidsmap.com/en/news/4D3D19A7-1502-4C3F-8190-B5B1ECDD03C8.asp?type=preview

    UK Africans ‘need more HIV help’
    http://newsvote.bbc.co.uk/mpapps/pagetools/print/news.bbc.co.uk/1/hi/health/7535685.stm

    New criteria proposed for late HIV diagnosis
    http://www.aidsmap.com/en/news/2B74706E-0ED7-4C3D-9F52-55043CBEBB92.asp?type=preview

    Financial support

    The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

    The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

    We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

    For a list of companies that support the UK-CAB please see the “about us” page.

    Meetings
    Meetings